Table 5. Non-Fatal Cardiovascular Events During Long-term Follow-up.
| Sertraline N=234 |
Placebo N=235 |
P-value | |
|---|---|---|---|
| Acute myocardial infarction, No. (%) | 10 (4.3) | 8 (3.4) | .63 |
| Arrhythmia, No. (%) | 17 (7.3) | 20 (8.5) | .61 |
| Cardiac syncope, No., (%) | 6 (2.6) | 6 (2.6) | .99 |
| Cerebrovascular accident, No. (%) | 10 (4.3) | 4 (1.7) | .1 |
| Exacerbation of heart failure, No. (%) | 64 (27.4) | 68 (28.9) | .7 |
| Unstable angina, No. (%) | 23 (9.8) | 19 (8.1) | .51 |
| *Other cardiovascular event, No. (%) | 50 (21.4) | 59 (25.1) | .34 |
*
Includes: wound infection, peripheral vascular disease, acute renal failure, drainage drive line, hypertensive urgency, presyncope, accelerated hypotension, hypotension, deep vein thrombosis, prerenal azotemia, graft thrombosis, non-unstable angina chest pain.